The Patent Clock Is Ticking—And the Best Talent Isn’t Waiting for You
Most pharma teams treat “talent” like a hiring problem. But in a world where exclusivity windows, patent cliffs, and regulatory timelines move faster than org charts, talent is also …
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking Read Post »
Pharma patent litigation is often described as a battle of legal teams and courtroom strategy. But the real cost is rarely the line item everyone can see.
It’s the opportunity cost. The operational drag. The delayed launches. The regulatory uncertainty…
What Pharma Patent Litigation Actually Costs (It’s Not the Legal Bills) Read Post »
Australia’s “drug patent clock” is one of those phrases that sounds simple—until you look under the hood. In practice, the time a medicine is protected isn’t a single number on a calendar. It’s a moving target shaped by patent terms, regulatory exclusi…
Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts Read Post »
Pharma’s “reformulation playbook” is getting louder—and investors should pay attention.
For years, the market narrative has been simple: when a blockbuster’s patent clock runs out, generics rush in, prices fall, and revenue declines. But the industry…
Drug spend is not a mystery problem—it’s a timing problem.
If your organization is still negotiating drug prices without a clear view of when exclusivity ends, you’re not managing cost—you’re guessing. And in today’s market, guessing can be the diffe…
Patent Expiration Data: The Procurement Playbook That Cuts Your Drug Spend by 80% Read Post »
The “Drug Patent Cliff” Isn’t a Theory—It’s a Procurement Schedule.
If you manage sourcing, contracting, or supply continuity, you already know the uncomfortable truth: the biggest cost swings in healthcare rarely arrive as a surprise. They arrive as a…
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook Read Post »
The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Imperil Sponsor Patents
Clinical development is supposed to be a race against time—enrolling patients, generating data, and moving assets toward approval. But there’s a quieter race …
The “Hard 20” in New Zealand Isn’t Just a Patent Rule—It’s a Business Model.
In New Zealand, the clock doesn’t merely tick on drug patents—it dictates how generics are financed, timed, and launched.
Drug Patent Watch’s latest deep dive into New Zealand…
Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…
Patent Term Extensions: The Most Misunderstood Dates in Pharma Read Post »
Pharma has a patent problem—and a tax problem.
For years, the industry has treated IP strategy like a pure play offense: file early, extend late, defend aggressively, monetize relentlessly. But the modern reality is that the “value” of a patent isn’t j…
Patent Box Tax Strategy: The Definitive Guide to Pharma IP Tax Optimization Read Post »
Get new actionable insights and updates from BiotechBlog
